MRK vs. NVO
Compare and contrast key facts about Merck & Co., Inc. (MRK) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: MRK or NVO.
Correlation
The correlation between MRK and NVO is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
MRK vs. NVO - Performance Comparison
Key characteristics
MRK:
-0.71
NVO:
-0.70
MRK:
-0.85
NVO:
-0.80
MRK:
0.88
NVO:
0.89
MRK:
-0.55
NVO:
-0.55
MRK:
-1.09
NVO:
-1.48
MRK:
13.59%
NVO:
17.13%
MRK:
21.03%
NVO:
36.27%
MRK:
-68.62%
NVO:
-71.31%
MRK:
-25.27%
NVO:
-46.24%
Fundamentals
MRK:
$247.70B
NVO:
$352.92B
MRK:
$4.78
NVO:
$2.93
MRK:
20.49
NVO:
26.86
MRK:
0.07
NVO:
1.28
MRK:
$48.59B
NVO:
$204.72B
MRK:
$36.68B
NVO:
$173.22B
MRK:
$19.73B
NVO:
$108.42B
Returns By Period
In the year-to-date period, MRK achieves a -1.57% return, which is significantly higher than NVO's -8.52% return. Over the past 10 years, MRK has underperformed NVO with an annualized return of 8.34%, while NVO has yielded a comparatively higher 15.65% annualized return.
MRK
-1.57%
-0.43%
-21.00%
-15.14%
5.64%
8.34%
NVO
-8.52%
-25.74%
-39.95%
-26.03%
22.75%
15.65%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
MRK vs. NVO — Risk-Adjusted Performance Rank
MRK
NVO
MRK vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Merck & Co., Inc. (MRK) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
MRK vs. NVO - Dividend Comparison
MRK's dividend yield for the trailing twelve months is around 3.19%, more than NVO's 1.83% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRK Merck & Co., Inc. | 3.19% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% | 3.12% |
NVO Novo Nordisk A/S | 1.83% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
Drawdowns
MRK vs. NVO - Drawdown Comparison
The maximum MRK drawdown since its inception was -68.62%, roughly equal to the maximum NVO drawdown of -71.31%. Use the drawdown chart below to compare losses from any high point for MRK and NVO. For additional features, visit the drawdowns tool.
Volatility
MRK vs. NVO - Volatility Comparison
The current volatility for Merck & Co., Inc. (MRK) is 5.47%, while Novo Nordisk A/S (NVO) has a volatility of 21.75%. This indicates that MRK experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
MRK vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Merck & Co., Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities